Compugen to Release Fourth Quarter and Full Year 2023 Results on Tuesday, March 5, 2024

Rhea-AI Summary

Compugen Ltd. announced the release of its fourth quarter and full year 2023 financial results on March 5, 2024. The company, known for its computational target discovery in cancer immunotherapy, will host a conference call to discuss the results and provide a corporate update.

HOLON, Israel, Feb. 20. 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that the Company will release its fourth quarter and full year 2023 financial results on Tuesday, March 5, 2024, before the U.S. financial markets open. Management will host a conference call and webcast to review the results and provide a corporate update at 8:30 AM ET.

To access the live conference call by telephone, please dial 1-866-744-5399 from the U.S., or +972-3-918-0644 internationally. The call will be available via live webcast through Compugen's website, located at the following link.

Following the live webcast, a replay will be available on the Company's website.

About Compugen

Compugen is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify new drug targets and biological pathways for developing cancer immunotherapies. Compugen has developed two proprietary product candidates: COM701, a potential first-in-class anti-PVRIG antibody and COM902, a potential best-in-class antibody targeting TIGIT for the treatment of solid tumors. Compugen also has a clinical stage partnered program, rilvegostomig (previously AZD2936), a PD-1/TIGIT bispecific antibody where the TIGIT component is derived from Compugen's clinical stage anti-TIGIT antibody, COM902, in Phase 3 development by AstraZeneca through a license agreement for the development of bispecific and multispecific antibodies. In addition, Compugen's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, of which the most advanced program, in IND enabling studies is COM503, which is licensed to Gilead. COM503 is a potential first-in-class, high affinity antibody which blocks the interaction between IL-18 binding protein and IL-18, thereby freeing natural IL-18 in the tumor microenvironment to inhibit cancer growth. Compugen is headquartered in Israel, with offices in San Francisco, CA. Compugen's shares are listed on Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol CGEN. 

Company contact:

Yvonne Naughton, Ph.D.
Head of Investor Relations and Corporate Communications
Email: ir@cgen.com
Tel: +1 (628) 241-0071  

View original content:https://www.prnewswire.com/news-releases/compugen-to-release-fourth-quarter-and-full-year-2023-results-on-tuesday-march-5-2024-302065833.html

SOURCE Compugen Ltd.

FAQ

When will Compugen Ltd. release its fourth quarter and full year 2023 financial results?

Compugen Ltd. will release its fourth quarter and full year 2023 financial results on Tuesday, March 5, 2024, before the U.S. financial markets open.

What is Compugen Ltd.'s ticker symbol?

Compugen Ltd.'s ticker symbol is CGEN.

How can I access the conference call discussing Compugen Ltd.'s financial results?

To access the live conference call by telephone, dial 1-866-744-5399 from the U.S., or +972-3-918-0644 internationally. The call will also be available via live webcast through Compugen's website.

Will there be a replay available for the conference call?

Yes, a replay of the conference call will be available on Compugen Ltd.'s website following the live webcast.